* MAT BIOPHARMA *
2000 - IDF
Évry
(near Paris)
www.matbiopharma.fr Discovery, Drugs
Key words: MABs, Antibody-based therapeutics, Cancer, Immuno-therapy, Angiogenesis
Mission: to develop proprietary antibody-based therapeutics for the treatment of cancer
Clients: Pharmaceutical industry (own development up to phase II included)
contact@matbiopharma.fr
Age: 10 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS | | Personal venture |
Managing Dir.-CEO: Vallet (François) [born 1958, Polytechnique, Ph.D. physics, ex-Genewave (co-founder)]
Sc.Dir.-CSO: Boumsell (Laurence)
Fin.Dir.-CFO: vacant
BusDev: vacant
Financers (Hist.): Génopole 1er Jour, IxCore, Anvar
Note : full company legal name is Monoclonal Antibodies Therapeutics | Turnover (M€) : 0.05 (2004)
Total funding (M€) : 5.8
Last funding (M€) : 5.8
Focus : Cancers
Position : Clinical
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME | | 2009 .01 | Nomination : François Vallet, as CEO | ORGN | [8 years] |
| 2008 .09 | Clinical trial (phase II) for Ferritarq (completed) | CLIN | [8 years] |
| 2006 .09 | Registration : orphan Drug designation by EMEA for Ferritarq | MKTG | [6 years] |
| 2006 .02 | Partnering research agreement with Pierre Fabre, on anticancer MABs | R&D | [6 years] |
| 2005 .01 | Partnering research agreement with Servier, on anticancer MABs | R&D | [4 years] |
| 2002 .11 | Round-financing : 1.25 M€, by undisclosed investors | RFIN | [2 years] |
| 2000 .02 | Company founded by Dr Jean Kadouche [born 1945, initial CEO], Raphaël Lévy [M.D., Laennec], Bernard Montanari (initially named Monoclonal Antibodies Therapeutics) | ORGF | [0 year] | Actualisation / Updating: 08-Mars-2010 |
|
